FDA rejects Merck’s Vioxx Successor

Today, Merck announced that the FDA rejected its request to market a successor to its withdrawn arthritis drug Vioxx in the U.S. The move was widely expected after a panel of FDA advisers two weeks ago voted 20-1 against approving the drug Arcoxia.

For the full article.

Lawyer Monthly - Legal Awards Winner
The National Trial Lawyers
Elder Care Matters Alliance
American Association for Justice
Fellow Litigation Counsel of America
Super Lawyers